Derived from an analysis of 82 SCLC single-cell transcriptomes and six phase II trials, it robustly identifies DDR-IF-high tumors, which are characterized by cGAS-STING pathway exhaustion, reduced CD8+ TIL infiltration, and a superior pooled objective response rate (ORR) to PARP-ICB combinations (42% vs. 18%) (5, 6). The gene discussed is PARP1; the disease is small cell lung carcinoma.